

Cumulated Subject Index Vol. 9/10, 1975

A

- Acidosis, lactic
 - diabetes 10: 70-71
- Adenosine diphosphate
 - platelet aggregation 9: 28-30
- Adrenal crisis, acute neonatal
 - corticosteroids 10: 435
- Adrenal function
 - beclomethasone dipropionate inhaler 10: 197
 - compared with
 - corticosteroids, oral 10: 200-202
 - patient management 10: 208
 - beclomethasone dipropionate intranasal 10: 212
- Adrenaline
 - platelet aggregation 9: 31
- Adrenergic receptor blocking drugs
 - platelet function 9: 52
- α -Adrenergic receptor blocking drugs
 - spasticity 10: 120
- β -Adrenergic receptor blocking drugs
 - in renal failure 9: 153
- practolol
 - drug reactions, adverse 10: 336-341
 - timolol 9: 165-176
- Adrenocorticotrophic hormone
 - rheumatoid arthritis 10: 417
- Adrenogenital syndrome
 - children
 - corticosteroids 10: 434-435
- Aggression
 - tranquillisers 10: 157
- Alclofenac
 - rheumatic disorders 9: 323
 - rheumatoid arthritis 10: 412
- Alcohol
 - platelet function 9: 48
- Alprenolol
 - compared with
 - timolol 9: 165-166
- Amiloride 9: 193-195
 - drug reactions, adverse 9: 215
- Aminoglycosides 10: 92-108
 - framycetin 10: 106-108
 - gentamicin 10: 99-103
 - kanamycin 10: 94-98
 - neomycin 10: 106-108
 - paromomycin 10: 106-108
 - streptomycin 10: 92-94
 - tobramycin 10: 103-106
- Amoxycillin 9: 85-87, 88-140; 10: 27
 - absorption 9: 98-106, 10: 228
 - effect of age 9: 102-103
 - effect of probenecid 9: 103-104
 - half-life 9: 105-106
 - influence of food 9: 104
 - in impaired renal function 9: 104-105
 - antibacterial activity 9: 93-98
 - in vitro* 9: 93-97
 - in vivo* 9: 97-98
 - compared with ampicillin 9: 85-87, 93-111, 117-133
 - contra-indications 9: 133
 - distribution 9: 106-112; 10: 228
 - animals 9: 109
 - aqueous humor 9: 109
 - bile 9: 107
 - bone marrow 9: 108
 - breast milk 9: 108
 - cerebrospinal fluid 9: 108
 - interstitial fluid 9: 108
 - pregnancy 9: 108-109
 - protein binding 9: 109
 - sputum and saliva 9: 106-107
 - upper respiratory tract 9: 108
 - dosage 9: 134-135
 - gonorrhoea 9: 134
 - in renal failure 9: 135
 - paediatric 9: 134-135
 - routine use 9: 134
 - drug reactions, adverse 9: 130-132
 - gastro-intestinal 9: 132
 - skin rashes 9: 130-131
 - compared with
 - ampicillin 9: 131-132
 - penicillin V 9: 132
 - laboratory abnormalities 9: 132-133
 - metabolism and excretion 9: 110-112
 - effect of dialysis 9: 112
 - influence of food 9: 111
 - in renal failure 9: 110-111
 - neonate 9: 111
 - pharmacodynamic effects 9: 112
 - antigenicity 9: 112-113
 - pharmacokinetics 9: 98-112
 - precautions 9: 133
 - therapeutic trials 9: 113-130
 - biliary infections 9: 129
 - bone infections 9: 129-130
 - endocarditis 9: 129
 - gastro-intestinal infections 9: 127-129

Cumulated Subject Index Vol. 9/10, 1975

A

- Acidosis, lactic
 - diabetes 10: 70-71
- Adenosine diphosphate
 - platelet aggregation 9: 28-30
- Adrenal crisis, acute neonatal
 - corticosteroids 10: 435
- Adrenal function
 - beclomethasone dipropionate inhaler 10: 197
 - compared with
 - corticosteroids, oral 10: 200-202
 - patient management 10: 208
 - beclomethasone dipropionate intranasal 10: 212
- Adrenaline
 - platelet aggregation 9: 31
- Adrenergic receptor blocking drugs
 - platelet function 9: 52
- α -Adrenergic receptor blocking drugs
 - spasticity 10: 120
- β -Adrenergic receptor blocking drugs
 - in renal failure 9: 153
- practolol
 - drug reactions, adverse 10: 336-341
 - timolol 9: 165-176
- Adrenocorticotrophic hormone
 - rheumatoid arthritis 10: 417
- Adrenogenital syndrome
 - children
 - corticosteroids 10: 434-435
- Aggression
 - tranquillisers 10: 157
- Alclofenac
 - rheumatic disorders 9: 323
 - rheumatoid arthritis 10: 412
- Alcohol
 - platelet function 9: 48
- Alprenolol
 - compared with
 - timolol 9: 165-166
- Amiloride 9: 193-195
 - drug reactions, adverse 9: 215
- Aminoglycosides 10: 92-108
 - framycetin 10: 106-108
 - gentamicin 10: 99-103
 - kanamycin 10: 94-98
 - neomycin 10: 106-108
 - paromomycin 10: 106-108
 - streptomycin 10: 92-94
 - tobramycin 10: 103-106
- Amoxycillin 9: 85-87, 88-140; 10: 27
 - absorption 9: 98-106, 10: 228
 - effect of age 9: 102-103
 - effect of probenecid 9: 103-104
 - half-life 9: 105-106
 - influence of food 9: 104
 - in impaired renal function 9: 104-105
 - antibacterial activity 9: 93-98
 - in vitro* 9: 93-97
 - in vivo* 9: 97-98
 - compared with ampicillin 9: 85-87, 93-111, 117-133
 - contra-indications 9: 133
 - distribution 9: 106-112; 10: 228
 - animals 9: 109
 - aqueous humor 9: 109
 - bile 9: 107
 - bone marrow 9: 108
 - breast milk 9: 108
 - cerebrospinal fluid 9: 108
 - interstitial fluid 9: 108
 - pregnancy 9: 108-109
 - protein binding 9: 109
 - sputum and saliva 9: 106-107
 - upper respiratory tract 9: 108
 - dosage 9: 134-135
 - gonorrhoea 9: 134
 - in renal failure 9: 135
 - paediatric 9: 134-135
 - routine use 9: 134
 - drug reactions, adverse 9: 130-132
 - gastro-intestinal 9: 132
 - skin rashes 9: 130-131
 - compared with
 - ampicillin 9: 131-132
 - penicillin V 9: 132
 - laboratory abnormalities 9: 132-133
 - metabolism and excretion 9: 110-112
 - effect of dialysis 9: 112
 - influence of food 9: 111
 - in renal failure 9: 110-111
 - neonate 9: 111
 - pharmacodynamic effects 9: 112
 - antigenicity 9: 112-113
 - pharmacokinetics 9: 98-112
 - precautions 9: 133
 - therapeutic trials 9: 113-130
 - biliary infections 9: 129
 - bone infections 9: 129-130
 - endocarditis 9: 129
 - gastro-intestinal infections 9: 127-129

- gonorrhoea 9: 118–122
 lower respiratory tract infections 9: 122–124
 skin and soft tissue infections 9: 127
 upper respiratory tract infections 9: 124–126
 urinary tract infections 9: 114–118
- Amphotericin B
 fungal infections 9: 401–402
- Ampicillin 9: 81–87; 10: 23–27
 compared with
 amoxycillin 9: 85–87, 93–111, 117–133; 10: 228
 dosage 10: 25
 drug reactions, adverse 10: 25–27
 colitis 10: 330–331
 respiratory infections 10: 442
 therapeutic use 10: 24–25
 typhoid fever 9: 241–242, 244–245, 248–249, 317
- Anaemia, hypoplastic
 phenylbutazone 9: 310–311
- Anaesthesia, halothane
 jaundice, postoperative 9: 311–313; 10: 233–235
- Anaesthesia, morphine
 + nitrous oxide
 cardiovascular effects 9: 383–385
- Anaesthetics
 pregnancy 10: 152
- Anaesthetics, general
 platelet function 9: 48
- Analgesia, postoperative 9: 373–380
 analgesia, regional 9: 379–380
 epidural blocks 9: 379–380
 infiltration analgesia 9: 379
 analgesics, inhalational 9: 378
 analgesics, strong 9: 376–378
 narcotics 9: 376–378
 non-narcotics 9: 378
 drugs 9: 376–380
 operation 9: 375–376
 patient 9: 373–375
 pathophysiological status 9: 374–375
 chronic disease 9: 375
 elderly 9: 374
 head injury 9: 375
 hypovolaemia 9: 375
 respiratory disease 9: 375
 psychological factors 9: 373
- Analgesics, mild 10: 368–390
 absorption 10: 381–383
 influence of tablet formulation 10: 381–382
 mechanism 10: 382
 other factors 10: 382–383
 assessment of 10: 368–371
 drug interactions 10: 387–388
 drug reactions, adverse 10: 383–387
 allergy 10: 383, 386
 gastric irritation 10: 383
 haemorrhage 10: 383
 hepatic damage 10: 386–387
 renal damage 10: 386
 history 10: 371
 pharmacology 10: 372–381
 antirheumatic drugs 10: 380
 aspirin 10: 373–375
 analgesic effect 10: 374
- anti-inflammatory effects 10: 374
 antipyretic effect 10: 374
 metabolic effects 10: 375
 prothrombin levels, effect on 10: 375
 respiration and acid-base balance, effect on 10: 374–375
 uricosuric effects 10: 375
- carbamazepine 10: 380–381
 codeine 10: 377
 dextropropoxyphene 10: 377
 dihydrocodeine 10: 377, 380
 ethoheptazine 10: 380
 flufenamic acid 10: 376
 mechanisms of action 10: 372–373
 central 10: 373
 peripheral 10: 372–373
 mefenamic acid 10: 376
 mixtures 10: 381
 paracetamol 10: 376
 phenacetin 10: 376
 site of action 10: 372
 non-therapeutic use 10: 390
 therapeutic use 10: 388–390
 acute painful conditions 10: 388–389
 chronic painful conditions 10: 389–390
- Angina pectoris
 timolol 9: 168–169
- Angio oedema 9: 292–293
- Ankylosing spondylitis
 antirheumatic drugs 10: 421
 naproxen 9: 351–352
- Anorectic drugs
 fenfluramine 10: 249–315
- Antacids
 ulcer, peptic 10: 58–60
- Anthranilates
 rheumatic disorders 9: 323
- Anthranilic acids
 flufenamic acid
 rheumatoid arthritis 10: 413
 meclofenamic acid
 rheumatoid arthritis 10: 413
 mefenamic acid
 rheumatoid arthritis 10: 413
- Antibacterial agents 10: 6–50, 82–108
 aminoglycosides 10: 92–108
 framycetin 10: 106–108
 antibacterial activity 10: 107
 drug reactions, adverse 10: 108
 pharmacokinetics 10: 107
 therapeutic use 10: 107–108
 gentamicin 10: 99–103
 antibacterial activity 10: 99–100
 dosage 10: 102–103
 drug reactions, adverse 10: 103
 pharmacokinetics 10: 100–101
 therapeutic use 10: 102
 kanamycin 10: 94–98
 antibacterial activity 10: 94–95
 dosage 10: 97–98
 drug reactions, adverse 10: 98
 pharmacokinetics 10: 95
 therapeutic use 10: 97

- neomycin 10: 106–108
 - antibacterial activity 10: 107
 - drug reactions, adverse 10: 108
 - pharmacokinetics 10: 107
 - therapeutic use 10: 107–108
- paromomycin 10: 106–108
 - antibacterial activity 10: 107
 - drug reactions, adverse 10: 108
 - pharmacokinetics 10: 107
 - therapeutic use 10: 107–108
- streptomycin 10: 92–94
 - antibacterial activity 10: 92–93
 - dosage 10: 93
 - drug reactions, adverse 10: 94
 - pharmacokinetics 10: 93
 - therapeutic use 10: 93
- tobramycin 10: 103–106
 - antibacterial activity 10: 104
 - dosage 10: 106
 - drug reactions, adverse 10: 106
 - pharmacokinetics 10: 104–105
 - therapeutic use 10: 105–106
- antiseptics, urinary 10: 47–50
- nalidixic acid 10: 49–50
 - antibacterial activity 10: 49
 - dosage 10: 50
 - drug reactions, adverse 10: 50
 - pharmacokinetics 10: 49–50
 - therapeutic use 10: 50
- nitrofurantoin 10: 47–49
 - antibacterial activity 10: 47
 - dosage 10: 48
 - drug reactions, adverse 10: 48–49
 - pharmacokinetics 10: 47–48
 - physico-chemical properties 10: 47
 - therapeutic use 10: 48
- oxolinic acid 10: 50
- cephalosporins 9: 308–309; 10: 82–89
- cephalexin 10: 87
- cephaloridine 10: 83–86
 - antibacterial activity 10: 83
 - dosage 10: 85
 - drug reactions, adverse 10: 85–86
 - pharmacokinetics 10: 83
 - therapeutic use 10: 84–85
- cephalothin 10: 86
- cephamycins 10: 88
- cephradine 10: 87
- derivatives, new 10: 88
- chloramphenicol 10: 34–35
 - therapeutic use 10: 34–35
 - enteric fever 10: 35
 - other 10: 35
- clindamycin 10: 42–45
 - antibacterial activity 10: 43
 - dosage 10: 44
 - drug reactions, adverse 10: 44–45
 - pharmacokinetics 10: 43–44
 - therapeutic use 10: 44
- co-trimoxazole 10: 28–34
 - antibacterial activity 10: 28–29
 - Gram-negative bacteria 10: 29
 - Gram-positive bacteria 10: 29
- contra-indications 10: 33
- drug reactions, adverse 10: 33–34
 - haematological abnormalities 10: 33–34
 - hypersensitivity 10: 34
 - nephrotoxicity 10: 34
- mode of action 10: 29–30
- pharmacokinetics 10: 30–31
- therapeutic use 10: 31–33
 - bacteraemic syndromes 10: 31
 - brucellosis 10: 33
 - chest infections 10: 32
 - enteric fever 10: 32
 - gonorrhoea 10: 32
 - urinary tract infections 10: 31
- fusidic acid 10: 45–47
 - antibacterial activity 10: 45
 - dosage 10: 46
 - drug reactions, adverse 10: 46–47
 - mode of action 10: 45
 - pharmacokinetics 10: 46
 - therapeutic use 10: 46
- in vitro* 9: 93–98
- in vivo* 9: 97–98
- lincomycin 10: 42–45
 - antibacterial activity 10: 43
 - dosage 10: 44
 - drug reactions, adverse 10: 44–45
 - pharmacokinetics 10: 43–44
 - therapeutic use 10: 44
- macrolides 10: 39–42
- erythromycin 10: 39–42
 - antibacterial activity 10: 39–46
 - dosage 10: 42
 - drug reactions, adverse 10: 42
 - therapeutic use 10: 41
 - pharmacokinetics 10: 40–41
 - physico-chemical properties 10: 39
- spiramycin 10: 42
- triacetyloleandomycin 10: 42
- penicillins, natural 10: 9–18
 - antibacterial activity 10: 12–13
 - against staphylococci 10: 12–13
 - against streptococci 10: 12
 - dosage
 - benzathine 10: 16
 - penicillin G 10: 15–16
 - penicillin V 10: 16
 - procaine penicillin 10: 16
 - drug reactions, adverse 10: 16–18
 - haemolysis 10: 17
 - hypersensitivity 10: 17–18
 - nephritis 10: 16
 - neurotoxicity 10: 16
 - penicillin V 10: 18
 - mode of action 10: 10–12
 - pharmacokinetics 10: 13–14
 - benzathine 10: 14
 - penicillin G 10: 13–14
 - penicillin V 10: 14
 - procaine penicillin 10: 14
 - physico-chemical properties 10: 10
 - therapeutic use 10: 14–15
 - gonorrhoea 10: 15

- meningococcal infections 10: 15
- other infections 10: 15
- streptococcal infections 10: 15
- penicillins, semi-synthetic 10: 18–28
- broad spectrum penicillins 10: 23–28
 - amoxycillin 10: 27
 - ampicillin 10: 23–27
 - dosage 10: 25
 - drug reactions, adverse 10: 25–27
 - therapeutic use 10: 24–25
 - carbenicillin 10: 27
 - dosage 10: 28
 - drug reactions, adverse 10: 28
 - therapeutic use 10: 28
 - carindacillin 10: 28
 - epicillin 10: 27
 - hetacillin 10: 27
 - pivampicillin 10: 27
- penicillinase-stable penicillins 10: 19–23
 - isoxazolyl penicillins 10: 20–23
 - drug reactions, adverse 10: 23
 - therapeutic use 10: 23
 - methicillin 10: 19–20
 - dosage 10: 20
 - therapeutic use 10: 20
 - phenoxypenicillins 10: 18–19
- peptide antibiotics 10: 89–91
- antibacterial activity 10: 89
- drug reactions, adverse 10: 91
- nephrotoxicity 10: 91
- neurotoxicity 10: 91
- pharmacokinetics 10: 89–90
- therapeutic use 10: 90–91
 - intrathecal 10: 91
 - oral 10: 91
 - parenteral 10: 90–91
 - topical 10: 90
- tetracyclines 10: 35–39
 - antibacterial activity 10: 36
 - resistance 10: 36
 - spectrum 10: 36
 - drug reactions, adverse 10: 38–39
 - liver toxicity 10: 39
 - renal toxicity 10: 38–39
 - tooth discolouration 10: 38
 - pharmacokinetics 10: 36–37
 - therapeutic use 10: 37
- sulphonamides 10: 6–9
 - antibacterial activity 10: 6
 - dosage 10: 8
 - drug interactions 10: 9
 - drug reaction, adverse
 - haematological abnormalities 10: 8
 - hypersensitivity 10: 9
 - nephrotoxicity 10: 8
 - pulmonary disease 10: 9
 - mode of action 10: 6
 - pharmacokinetics 10: 7
 - therapeutic use 10: 7–8
- Antibiotics
 - drug reactions, adverse
 - colitis, non-specific 10: 330–332
 - colitis, pseudomembranous 10: 330–332
 - diarrhoea 10: 329–332
 - penicillins 9: 308–309
- Antibiotics, broad spectrum
 - amoxycillin 9: 85–87, 88–40; 10: 27
 - ampicillin 9: 81–87; 10: 23–27
 - minocycline 9: 256–263
- Antibiotics, systemic
 - prophylaxis
 - in surgery 10: 154–155, 333–335
- Antibiotics, topical
 - in pyoderms 9: 157
- Anticholinergics
 - sleep 9: 470–471
 - ulcer, peptic 10: 60–61
- Anticoagulants
 - + antiplatelet drugs
 - thromboses 9: 60–61
 - + immunosuppressive agents
 - glomerulonephritis, rapidly progressive 10: 156–157
- Anticonvulsants
 - sodium valproate
 - epilepsy 9: 387–389
- Antidepressants
 - non-compliance 10: 69
 - sleep 9: 471
- Antidepressants, tricyclic
 - cardiovascular effects 10: 456–457
 - platelet function 9: 47
 - poisoning 10: 226–227
- Antifungal drugs 9: 401–405
 - amphotericin B 9: 401–402
 - clotrimazole 9: 426–445
 - 5-fluorocytosine 9: 404–405
 - imidazole derivatives 9: 402–405
 - miconazole 9: 407–422
- Antihistamines
 - sleep 9: 470–471
- Antihypertensives
 - prazosin 9: 158
- Anti-inflammatory agents
 - antirheumatic drugs 9: 321–324; 10: 397–423
- Anti-inflammatory drugs, non-steroid
 - platelet function, inhibition of 9: 38–43
- Antimalarials
 - rheumatoid arthritis 10: 413–414
- Antimicrobial prophylaxis
 - in urinary tract infection 9: 386–387
- Antiplatelet drugs
 - clinical use 9: 54–61
 - pharmacology 9: 19–54
- Antipyrene
 - plasma half-life 9: 228
- Antirheumatic drugs 9: 321–324; 10: 397–423
 - alclofenac 9: 323
 - ankylosing spondylitis 10: 421
 - anthranilates 9: 323
 - drug reactions, adverse 10: 422–423
 - ulcerogenic effect 10: 422–423
 - fenoprofen 9: 322
 - ibuprofen 9: 321–322
 - ketoprofen 9: 322

- naproxen 9: 322, 330-360
 osteoarthritis 10: 421-422
 pathogenesis of rheumatic disease 10: 397-400
 allergic and drug-induced arthritis 10: 400
 biochemical or endocrine factors 10: 399
 hereditary factors 10: 399
 immunological factors 10: 397-398
 infectious agents 10: 398-399
 neurogenic factors 10: 400
 proliferative disorders 10: 399-400
 trauma 10: 399
 D-penicillamine 9: 324
 pharmacokinetics 10: 403-404
 pharmacology 10: 380
 pharmacology of joint inflammation 10: 400-403
 kallikrein-kinin-kininase system 10: 400-401
 lysosomes 10: 401-402
 prostaglandins 10: 402-403
 protein binding 10: 402
 polymyalgia rheumatica 10: 422
 rheumatoid arthritis 10: 405-420
 treatment at level 1 10: 406-408
 general basic treatment 10: 406
 salicylates 10: 406-408
 treatment at level 2 10: 408-415
 anthranilic acids 10: 413
 flufenamic acid 10: 413
 mefenamic acid 10: 413
 antimalarials 10: 413-414
 corticosteroids, intra-articular 10: 414
 muscle relaxants 10: 415
 indomethacin 10: 408-409
 non-narcotic analgesics 10: 414
 dextropropoxyphene 10: 414
 paracetamol 10: 414
 others with mild anti-inflammatory activity 10: 412
 alclofenac 10: 412
 tolmetin 10: 412
 oxyphenbutazone 10: 408
 phenylalkanoic acids 10: 409-412
 fenoprofen 10: 410
 flurbiprofen 10: 412
 ibuprofen 10: 410
 ketoprofen 10: 412
 naproxen 10: 410-411
 phenylbutazone 10: 408
 tranquillizers 10: 415
 treatment at level 3 10: 415-417
 adrenocorticotrophic hormone 10: 417
 corticosteroids, oral 10: 416-417
 gold salts 10: 415-416
 treatment at level 4
 hospitalisation 10: 418
 treatment at level 5 10: 418-420
 azathioprine 10: 419
 cyclophosphamide 10: 418-419
 D-penicillamine 10: 419-420
 rheumatoid arthritis, juvenile 10: 420
 salicylates 9: 323-324
 therapeutic use 9: 321-325; 10: 404-405
 Antiseptics, urinary 10: 47-50
 Antiserotonin agents
 platelet function 9: 53
 Antithrombotic drugs
 prophylactic use 9: 1-3
 Arrhythmia, cardiac
 imipramine poisoning 10: 228-229
 Artherosclerosis
 see heart disease
 Aspirin
 bleeding 9: 234-235
 nephropathy, analgesic 10: 69-70
 pharmacology 10: 373-375
 analgesic effect 10: 374
 anti-inflammatory effect 10: 374
 antipyretic effect 10: 374
 metabolic effects 10: 375
 prothrombin levels, effect on 10: 375
 respiration and acid-base balance, effect on 10: 374-375
 uricosuric effects 10: 375
 platelet function 9: 38-43
 rheumatic disorders 9: 323-324
 compared with
 naproxen 9: 347-348
 + naproxen 9: 348-349
 thromboses, arterial 9: 55-56
 thromboses, venous postoperative 9: 55
 Asthma
 beclomethasone dipropionate inhaler 10: 76-77; 10: 161-164, 171-208
 therapeutic use 10: 175-190
 children
 corticosteroids 10: 432
 Azathioprine
 + co-trimoxazole 10: 71-72
 rheumatoid arthritis 10: 419

 B
 Baclofen
 spasticity 10: 118
 Bacteraemic syndromes
 co-trimoxazole 10: 31
 Barbiturates
 sleep 9: 465-467
 Barbiturate overdosage
 drug metabolism 10: 229-230
 BCG therapy
 leukaemia, myeloblastic 9: 391-392
 Beclomethasone dipropionate
 asthma 10: 76-77
 Beclomethasone dipropionate inhaler 10: 161-164, 171-208
 compared with
 corticosteroids, oral 10: 199-202
 adrenal function tests 10: 200-202
 insulin stress 10: 200-201
 tetracosactrin stimulation 10: 201-202
 dosage
 adults 10: 206
 children 10: 206
 drug reactions, adverse 10: 164, 202-205

- candidiasis, oral 10: 203-205
 systemic corticosteroid - withdrawal effects 10: 205
 patient management 10: 206-208
 adrenal function 10: 208
 asthmatics not receiving steroids 10: 207
 asthmatics, steroid-dependent 10: 207
 instructions 10: 206
 response 10: 206-207
 withdrawal symptoms 10: 208
 pharmacokinetics 10: 173-174
 absorption 10: 173-174
 excretion 10: 174
 half-life 10: 173
 metabolism 10: 174
 pharmacology 10: 171-173
 antigen-induced asthma, effect on 10: 171
 bronchial mucosa, effect on 10: 173
 eosinophils, effect on 10: 173
 hypothalamo-pituitary-adrenal function, effect on 10: 172-173
 topical activity 10: 171
 precautions 10: 205
 therapeutic trials 10: 175-190
 factors influencing response 10: 190-199
 adrenal function 10: 197
 age 10: 196-197
 allergy, presence of 10: 193-195
 asthmatics not receiving steroids 10: 188-190
 asthmatics, steroid dependent 10: 175-188
 children 10: 185-188
 long-term studies 10: 182-185
 short- and medium-term studies 10: 175-182
 dosage, beclomethasone dipropionate aerosol 10: 198-199
 dosage, oral corticosteroids 10: 191-193
 duration of maintenance corticosteroids 10: 196
 method of use 10: 199
 previous control 10: 197-198
 respiratory function 10: 195-196
 Beclomethasone dipropionate intranasal 10: 212-216
 adrenal function, effect on 10: 212
 compared with
 cromoglycate, sodium 10: 215
 dosage 10: 216
 drug reactions, adverse 10: 216
 polyps, nasal 10: 215
 precautions 10: 216
 rhinitis, perennial
 therapeutic trials 10: 214-215
 rhinitis, seasonal allergic 10: 212-216
 therapeutic trials 10: 212-214
 design 10: 212-213
 open 10: 214
 placebo-controlled 10: 213-214
 Bentonite
 poisoning, paraquat 9: 307
 Benzodiazepines
 sleep 9: 467-468
 Benzothiadiazines 9: 189-191
 drug reactions, adverse 9: 212-213
 Bioavailability
 after intramuscular injection 10: 67-68
 drugs 10: 144-147
 Bleeding
 aspirin 9: 234-235
 Blood coagulation
 platelets 9: 34-36
 Brom-ergocryptine
 lactation, inhibition of 10: 128-129
 Bronchial infections
 management 10: 448-449
 Bronchiolitis
 children
 corticosteroids 10: 432
 Bronchopneumonia
 management 10: 447-448
 Brucellosis
 co-trimoxazole 10: 33
 Bufenaxam 10: 352-356
 administration 10: 356
 drug reactions, adverse 10: 355
 mode of action 10: 353
 pharmacokinetics 10: 353
 pharmacology 10: 352
 anti-inflammatory activity 10: 352
 effect on wound healing 10: 352
 local tolerance 10: 352
 precautions 10: 356
 therapeutic trials 10: 353-355
 eczema 10: 353-355
 inflammatory dermatoses 10: 353-355
 psoriasis 10: 354
 Bumetanide 9: 5-18, 188-189
 ascites 9: 14-15
 biochemical effects 9: 10-13
 carbohydrate metabolism 9: 13
 contra-indications 9: 16
 diuretic effect 9: 7-9
 dosage 9: 16
 electrolyte excretion 9: 10-11
 frusemide failures 9: 15
 heart failure 9: 14
 oedema: local 9: 15
 oedema pulmonary 9: 14
 pharmacokinetics 9: 6-7
 pharmacology 9: 5-6, 7-13
 precautions 9: 16
 renal disease 9: 15
 side-effects 9: 16
 site of action 9: 13
 uric acid excretion 9: 12-13

 C
 Candidal infections 10: 140-141
 Candidiasis, oral
 beclomethasone dipropionate 10: 203-205
 Candidiasis, systemic
 clotrimazole 9: 442-443
 miconazole 9: 419-420
 Candidiasis, vaginal
 clotrimazole 9: 434-438
 miconazole 9: 413-415

- Carbamazepine
 compared with
 clonidine, low-dose 10: 360-361
- Carbamazepine
 pharmacology 10: 380-381
- Carbromal 9: 470
- Carbenicillin 10: 27-28
 dosage 10: 28
 drug reactions, adverse 10: 28
 therapeutic use 10: 28
- Carbenoxolone sodium
 ulcer, peptic 10: 58
- Cardiovascular effects
 antidepressants, tricyclic 10: 456-457
 nitrous oxide 9: 383-385
- Castellani's paint
 fungal skin infections 10: 134-136, 140-142
- Central nervous system
 fenfluramine 10: 257-259, 305-306
 neurotransmission
 dopamine 10: 458-459
- Cephalosporins 10: 82-89
 protein binding
 half-life
 distribution, volume of 9: 308-309
 respiratory infections 10: 444
- Cephalothin
 + cephapirin
 drug reactions, adverse 9: 382-383
- Cephapirin
 + cephalothin
 drug reactions, adverse 9: 382-383
- Chest infections
 co-trimoxazole 10: 32
- Childhood disease
 corticosteroids, use of 10: 426-436
- Children
 obesity
 fenfluramine 10: 292-295, 312
 rheumatoid arthritis 10: 420
- Children, hyperactive
 imipramine 9: 236-237
 methylphenidate 9: 237
- Chloral hydrate
 sleep 9: 469
- Chlorotrianesene
 lactation, inhibition of 10: 126-127
- Chloramphenicol
 drug reactions, adverse
 colitis 10: 330-331
 respiratory infections 10: 443
 therapeutic use 10: 34-35
 typhoid fever 9: 241-242, 244-246, 248, 317
- Chlorpromazine
 platelet function 9: 48
- Cholera
 minocycline 9: 283
- Chronic disease
 analgesia, postoperative 9: 375
- Clindamycin 10: 42-45
 drug reactions, adverse
 colitis 10: 331-332
 respiratory infections 10: 444
- Clofibrate
 heart disease 10: 220-224, 235-236
 platelet function 9: 49
 thrombo-embolic disease 9: 59
- Clonidine, low-dose 10: 358-365
 contra-indications 10: 364
 dosage 10: 365
 drug reactions, adverse 10: 364
 pharmacology 10: 358
 precautions 10: 364
 prophylaxis, migraine 10: 358-365
 efficacy decrease with time 10: 363-364
 therapeutic trials 10: 358-363
 factors influencing response 10: 362-363
 open trials 10: 359-362
 placebo-controlled 10: 359
- Clotrimazole 9: 403, 426-445
 administration 9: 445
 skin infections 9: 445
 vaginal infections 9: 445
 antimicrobial activity 9: 426-431
 antimicrobial activity 9: 429
 antibacterial activity 9: 429
 antifungal activity 9: 426-429
in vitro 9: 426-428
in vivo 9: 428-429
 antitrichomonal activity 9: 429
 mode of action 9: 429-430
 resistance 9: 430-431
 drug reactions, adverse 9: 444-445
 local therapy 9: 444
 systemic therapy 9: 444-445
 pharmacokinetic studies, animal 9: 431
 pharmacokinetic studies, human 9: 431-433
 administration, oral 9: 432-433
 absorption 9: 432
 excretion 9: 433
 metabolism 9: 432-433
 administration, topical 9: 431-432
 therapeutic trials 9: 434-443
 candidal paronychia 9: 441
 skin infections, bacterial 9: 441
 skin infections, fungal 9: 438-441
 candidal 9: 440
 compared with
 other antifungal agents 9: 441
 dermatophytosis 9: 439-440
 pityriasis versicolor 9: 441
 systemic therapy 9: 442-443
 aspergillosis 9: 443
 candidiasis 9: 442-443
 fungal endocarditis and mycetoma 9: 443
 vaginal infections 9: 434-438
 candidal vaginitis 9: 434-436
 compared with
 other anticanidial agents 9: 436-437
 trichomonal vaginitis 9: 438
 toxicology studies 9: 433-434
 dysmorphology and reproduction 9: 434
 toxicology, acute 9: 433
 toxicology, subacute and chronic 9: 433-434
- Codeine
 pharmacology 10: 377

- Colitis, non-specific
antibiotic-induced 10: 330-332
- Colitis, pseudomembranous
antibiotic-induced 10: 330-332
- Compression sclerotherapy
varicose veins 9: 392-393
- Congenital malformations
contraceptives, oral 10: 148-149
- Conjunctival infections
framycetin 10: 107
neomycin 10: 107
peptide antibiotics 10: 90
- Contraceptives, oral
congenital malformations 10: 148-149
hypertension 9: 230-231
urinary tract infection 10: 72-73
- Coronary heart disease
see heart disease
- Corticosteroids
childhood disease 10: 426-436
adrenal crisis, acute neonatal 10: 435
adrenogenital syndrome 10: 434-435
asthma 10: 432
bronchiolitis 10: 432
complications 10: 429-431
exacerbation of infections 10: 430-431
growth retardation 10: 431
dermatological conditions 10: 431
dosage 10: 427-429
initial 10: 427-428
maintenance 10: 428-429
reduction 10: 429
supplementary 10: 429
leukaemia, acute 10: 433
nephrotic syndrome 10: 435-436
pharmacophysiology 10: 426-427
purpura, idiopathic thrombocytopenia 10: 433-434
rheumatic carditis 10: 432-433
rheumatoid arthritis 10: 436
ulcerative colitis 10: 433
- Corticosteroids, aerosol
see beclomethasone dipropionate inhaler
- Corticosteroids, intra-articular
rheumatoid arthritis 10: 414
- Corticosteroids, oral
asthma 10: 161-164, 175-197, 199-202
rheumatoid arthritis 10: 416-417
- Corticosteroids, topical
bufexamac 10: 350-356
- Co-trimoxazole 10: 28-34
antibacterial activity 10: 49
+ azathioprine 10: 71-72
respiratory infections 10: 443
typhoid fever 9: 241-242, 244-246, 248-249
- Cromoglycate, sodium
compared with
beclomethasone dipropionate intranasal 10: 215
- Cyclacillin 9: 84-85
- Cyclophosphamide
rheumatoid arthritis 10: 418-419
- Cytotoxic agents
rheumatoid arthritis 10: 418-420

D

- Dantrolene sodium
spasticity 10: 119
- Deodorants
dermatitis 9: 235-236
- Dermatitis
deodorants 9: 235-236
- Dermatophyte infections 10: 130-139
- Dermatophytosis
clotrimazole 9: 439-440
miconazole 9: 415-417
- Dextran
platelet function 9: 49
thrombo-embolic disease 9: 59
- Dextropropoxyphene
pharmacology 10: 377, 380
rheumatoid arthritis 10: 414
- Diabetes
acidosis, lactic 10: 70-71
- Diabetes, experimental
islet cell transplantation 10: 151-152
- Diabetes insipidus
diuretics 9: 202-203
- Diabetes mellitus
maturity-onset diabetes
fenfluramine 10: 297-300
obese diabetes
fenfluramine 10: 296-297
- Diarrhoea
antibiotic-induced 10: 329-332
- Diazepam
administration
intramuscular 10: 451-452
oral 10: 451-452
- Diazepam
spasticity 10: 117-118
- Dietary fat
heart disease 9: 233-234
- Dipyridamole
platelet function 9: 44-46
thrombo-embolic disease 9: 58, 60
+ anticoagulants 9: 60-61
- Diuretics 9: 161-163, 180-215
classification 9: 185-195
benzothiadiazines 9: 189-191
bumetanide 9: 4-18, 188-189
ethacrynic acid 9: 186-187
frusemide 9: 187-188
heterocyclic variants of benzothiadiazines 9: 191-192
chlorthalidone 9: 191
clopamide 9: 192
clorexolone 9: 191
mefruside 9: 192
metolazone 9: 192
quinethazone 9: 192
osmotic diuretics 9: 195
isorbide 9: 195
potassium-sparing diuretics 9: 192-195
amiloride 9: 193-195
spironolactone 9: 193
triamterene 9: 193-194

- drug reactions, adverse 9: 209–215
 - amiloride 9: 215
 - benzothiadiazines 9: 212–213
 - carbohydrate intolerance 9: 211–212
 - electrolyte disorders 9: 209–211
 - alkalosis 9: 210
 - potassium deficiency 9: 210–211
 - sodium depletion 9: 209–210
 - ethacrynic acid 9: 214
 - frusemide 9: 213–214
 - hypokalaemia 9: 161–162
 - spironolactone 9: 214–215
 - triamterene 9: 215
- pharmacokinetics 9: 161–163, 180–185
 - anatomy 9: 180–181
 - site of action 9: 183–184
 - ascending limb of Henle's loop 9: 184
 - distal tubule 9: 184
 - proximal tubule 9: 183–184
 - potassium excretion 9: 185
 - sodium and water excretion 9: 181–183
 - reabsorption by ascending limb of Henle's loop 9: 182
 - reabsorption by collecting duct 9: 183
 - reabsorption by distal tubule 9: 182–183
 - reabsorption by proximal tubule 9: 181–182
- platelet function 9: 48
- therapeutic efficacy 9: 161–163, 195–209
 - diabetes insipidus 9: 202–203
 - hypertension 9: 203–206
 - essential 9: 204–206
 - associated with hyperaldosteronism 9: 203–204
 - oedema 9: 195–202
 - cirrhotic oedema and ascites 9: 201–202
 - heart failure 9: 196–198
 - left ventricular failure 9: 198–201
 - other uses 9: 208–209
 - pregnancy 9: 207–208
 - renal failure 9: 206–207
- Dopamine
 - neurotransmission 10: 458–459
- Drug interactions
 - analgesics 10: 387–388
 - aspirin 9: 359
 - fenfluramine +
 - antihypertensives 10: 308
 - cardiovascular drugs 10: 308
 - monoamine oxidase inhibitors 10: 309
 - psychotropic drugs 10: 308–309
 - minocycline 9: 286–287
 - naproxen 9: 359–360
 - sulphonamides 10: 9
 - timolol 9: 176
- Drug metabolism
 - barbiturate overdosage 10: 229–230
 - paracetamol overdosage 10: 229–230
- Drug metabolism, impairment of
 - in liver disease 10: 68
- Drug reactions, adverse 10: 230–232
 - amoxycillin 9: 130–132
 - ampicillin 10: 25–27, 330–331
 - anaesthesia, halothane 9: 311–313
 - anaesthetics
 - pregnancy 10: 152
 - analgesics 10: 383–387
 - antidepressants, tricyclic 10: 456–457
 - antirheumatic drugs 10: 422–423
 - aspirin 9: 234–235; 10: 69–70
 - baclofen 10: 118
 - barbiturates 9: 467
 - beclomethasone dipropionate inhaler 10: 164
 - beclomethasone dipropionate intranasal 10: 216
 - benzodiazepines 9: 468
 - bufexamac 10: 355
 - carbenicillin 10: 27–28
 - cephaloridine 10: 85–86
 - cephalothin and cephradine 9: 382–383
 - chloral hydrate 9: 469
 - chloramphenicol 10: 330–331
 - chlorpheniramine 10: 460
 - clindamycin 10: 44–45, 331–332
 - clonidine, low-dose 10: 364
 - clotrimazole 9: 444–445
 - contraceptives, oral 9: 230–231; 10: 148–149
 - co-trimoxazole 10: 33–34
 - dantrolene sodium 10: 119
 - diuretics 9: 161–162, 209–215
 - amiloride 9: 215
 - benzothiadiazines 9: 212–213
 - ethacrynic acid 9: 214
 - frusemide 9: 213–214, 231–232
 - spironolactone 9: 214–215
 - triamterene 9: 215
 - erythromycin 10: 42
 - fenfluramine 10: 303–308
 - alopecia 10: 306
 - central nervous system effects 10: 305–306
 - dry mouth 10: 306
 - gastro-intestinal effects 10: 303
 - hypotension 10: 304
 - sexual function 10: 307
 - skin disorders 10: 306
 - urinary frequency 10: 306
 - framycetin 10: 108
 - fusidic acid 10: 46–47
 - gentamicin 10: 103
 - halothane 10: 233–235
 - indomethacin 10: 460
 - isoxazolyl penicillins 10: 23
 - kanamycin 10: 98
 - lincomycin 10: 44–45, 331–332
 - metabolic activation 10: 454–456
 - miconazole 9: 420–421
 - minocycline 9: 284–286
 - nalidixic acid 10: 50
 - naproxen 9: 357–359
 - neomycin 10: 108
 - nitrofurantoin 10: 48–49
 - nitrous oxide 10: 461–463
 - oxytetracycline 10: 232
 - paromomycin 10: 108
 - penicillin 10: 330–331
 - penicillins, natural 10: 16–18
 - peptide antibiotics 10: 91
 - phenobarbitone 10: 453–454

practolol *10*: 149-151, 336-341
 sex hormones, synthetic *10*: 153-154
 streptomycin *10*: 94
 sulphonamides *10*: 8-9
 tetracyclines *10*: 38-39, 330-331
 timolol *9*: 175
 tobramycin *10*: 106
 tranquillisers *10*: 157

Drugs

bioavailability *10*: 144-147
 Dysmorphogenesis
 fenfluramine *10*: 261-262

E

Ear infections

framycetin *10*: 107
 neomycin *10*: 107
 peptide antibiotics *10*: 90

Eczema

bufexamac *10*: 353-355

Elderly

analgesia, postoperative *9*: 374

Enteric fever

chloramphenicol *10*: 35
 co-trimoxazole *10*: 32

Enterococcal endocarditis

gentamicin
 + penicillin *10*: 102

Epicillin *9*: 84; *10*: 27

Epilepsy

sodium valproate *9*: 387-389

Erythrasma *10*: 141-142

Erythromycin

respiratory infections *10*: 443

Ethacrynic acid *9*: 186-187

drug reactions, adverse *9*: 214
 platelet function *9*: 48

Ethchlorvynol

sleep *9*: 471

Ethoheptazine

pharmacology *10*: 380

F

Fenfluramine *10*: 249-315

contra-indications *10*: 311
 dependence potential *10*: 310-311
 dosage *10*: 314-315
 drug interactions *10*: 308-310
 antihypertensives *10*: 308
 cardiovascular drugs *10*: 308
 hypoglycaemic agents *10*: 309
 monoamine oxidase inhibitors *10*: 309
 psychotropic drugs *10*: 308-309
 drug reactions, adverse *10*: 303-308
 alopecia *10*: 306
 central nervous system effects *10*: 305-306
 depression *10*: 305
 dizziness *10*: 305
 dreams *10*: 306

drowsiness *10*: 305epileptics, effect on *10*: 306stimulant effects *10*: 305dosage *10*: 307dry mouth *10*: 306duration of treatment *10*: 308gastro-intestinal effects *10*: 303hypotension *10*: 304sexual function *10*: 307skin disorders *10*: 306urinary frequency *10*: 306obesity *10*: 249-250overdosage *10*: 312-314clinical features *10*: 312-313treatment *10*: 313-314pharmacodynamics *10*: 250-262analgesic activity *10*: 260anorectic activity *10*: 252-253mechanism *10*: 253sites *10*: 252-253anticonvulsant activity *10*: 259anti-tremorine activity *10*: 260body temperature, effect on *10*: 259cardiovascular effects *10*: 256-257central nervous system effects *10*: 257-259sedative effects *10*: 257-258sleep, effect on *10*: 258-259diuresis, effect on *10*: 259metabolic effects *10*: 253-256balance *10*: 253-256glucose metabolism *10*: 254-255growth hormone secretion *10*: 256lipid metabolism *10*: 255-256toxicology studies *10*: 260-262dysmorphology *10*: 261-262reproduction *10*: 261-262toxicity, acute *10*: 260toxicity, chronic *10*: 261toxicity, sub-acute *10*: 260-261water intake, effect on *10*: 259pharmacokinetics *10*: 262-267absorption *10*: 262-264administration, multiple-dose *10*: 263administration, single-dose *10*: 262-263bioavailability *10*: 262half-life *10*: 263plasma levels *10*: 263-264distribution *10*: 264-265placental transfer *10*: 265excretion *10*: 266-267metabolism *10*: 266-267precautions *10*: 312children *10*: 312dependence *10*: 312depression *10*: 312drug reactions, adverse *10*: 312therapeutic trials *10*: 267-303diabetes mellitus *10*: 295-300maturity-onset diabetes *10*: 297-300obese diabetes *10*: 296-297design *10*: 267-270obesity, adult *10*: 270-292cardiovascular disorders *10*: 289-290

- compared with
 - other anorectics 10: 270-272
 - corticosteroid therapy 10: 290-291
 - dosage related to efficacy 10: 283-285
 - factors affecting use 10: 272-283
 - hypertension 10: 287-289
 - motor disorders 10: 291-292
 - pregnancy 10: 292
 - psychiatric disorders 10: 292
 - pulmonary disease 10: 290
 - tolerance 10: 285-286
 - obesity, childhood 10: 292-295
 - with dietary restriction 10: 294-295
 - without dietary restriction 10: 293
 - psychiatric disorders 10: 300-302
 - alcoholism 10: 302
 - amphetamine-dependence 10: 300-301
 - anxiety 10: 300
 - mania 10: 300
 - tobacco-dependence 10: 301
 - skin disorders 10: 302-303
 - acne vulgaris 10: 302
 - pigmented naevi 10: 303
 - psoriasis 10: 302-303
 - Fenoprofen
 - platelet function 9: 39, 41
 - rheumatic disorders 9: 322
 - compared with
 - naproxen 9: 349-351
 - rheumatoid arthritis 10: 410
 - Fibrinogen degradation products
 - platelet function 9: 50
 - Flufenamic acid
 - pharmacology 10: 376
 - rheumatic disorders
 - compared with
 - naproxen 9: 351
 - rheumatoid arthritis 10: 413
 - 5-Fluorocytosine
 - fungal infections 9: 404-405
 - Flurazepam
 - sleep 9: 467-468
 - Flurbiprofen
 - rheumatoid arthritis 10: 412
 - Framycetin 10: 106-108
 - Fruzemide 9: 187-188
 - drug reactions, adverse 9: 213-214
 - platelet function 9: 48
 - Fusidic acid 10: 45-47
 - Fungal infections 9: 401-405
 - clotrimazole 9: 434-443
 - miconazole 9: 412-420
 - Fungal skin infections 10: 130-142
 - candidal infections 10: 140-141
 - dermatological manifestations 10: 140
 - paronychia, chronic 10: 140-141
 - dermatophyte infections 10: 130-139
 - diagnosis 10: 130-131
 - tinea barbae 10: 137
 - tinea capitis 10: 131-134
 - favus 10: 133-134
 - tinea corporis 10: 134
 - tinea cruris 10: 134-135
 - tinea faciei 10: 137-138
 - tinea imbricata 10: 138-139
 - tinea pedis 10: 135-136
 - tinea interdigitale 10: 136
 - tinea of the sole 10: 136
 - tinea unguium 10: 137
 - tinea versicolor 10: 138
 - treatment 10: 130-131
 - erythrasma 10: 141-142
 - punctate keratolysis 10: 142
 - Fungal infections, oropharyngeal
 - beclomethasone dipropionate inhaler
 - drug reactions, adverse 10: 203-205
- G
- Gallstones 10: 342-350
 - cholesterol solubility
 - in bile 10: 342-343
 - functional defects 10: 344
 - metabolic defects 10: 343-344
 - therapeutics 10: 345-346
 - bile acids 10: 345
 - chenodeoxycholic acid 10: 346-349
 - cessation of treatment 10: 349
 - results of treatment 10: 346-347
 - selection of patients 10: 349
 - side-effects 10: 347, 349
 - diarrhoea 10: 347
 - serum lipids 10: 347
 - serum transaminase levels 10: 347
 - toxic effects in rhesus monkeys 10: 347
 - future 10: 349-350
 - role of chenodeoxycholic acid 10: 349-350
 - role of preventative therapy 10: 350
 - other agents
 - anionic resins 10: 346
 - clofibrate 10: 346
 - detergent compounds 10: 346
 - phenobarbitone 10: 346
 - phospholipids 10: 346
 - Gastro-intestinal disease
 - antirheumatic drugs 10: 422-423
 - naproxen 9: 345
 - Gentamicin 10: 99-103
 - Glomerulonephritis, rapidly progressive
 - immunosuppressive agents
 - + anticoagulants 10: 156-157
 - Glucagon
 - platelet function 9: 53
 - Glucose metabolism
 - fenfluramine 10: 254-255
 - Glutethimide
 - sleep 9: 470
 - Glycerol
 - surgery, intra-cranial 9: 313-314
 - Glycerol-induced haemolysis
 - haemoglobinuria 9: 313-314
 - renal failure, acute 9: 313-314
 - Gold
 - rheumatoid arthritis 9: 155-156; 10: 415-416

Gonorrhoea

- co-trimoxazole 10: 32
- minocycline 9: 276-277
- penicillins, natural 10: 15

Gout, acute

- naproxen 9: 354-355

Griseofulvin

- fungal skin infections 10: 131-135, 137-139

Growth hormone secretion

- fenfluramine 10: 256

Guaiphenesin

- platelet function 9: 49

H

Haemolysis, glycerol-induced

- haemoglobinuria 9: 313-314
- renal failure, acute 9: 313-314

Haemoperfusion, charcoal

- in poisoned patients 10: 143-144

Halothane

- jaundice, postoperative 9: 311-313; 10: 233-235

Headaches, migrainous

- prophylaxis
- clonidine, low-dose 10: 358-365

Head injury

- analgesia, postoperative 9: 375

Heart disease 10: 218-224

- dietary fat 9: 233-234
- prevention of
- lipid lowering drugs 10: 223-224
- therapeutic trials 10: 219-222
- dietary manipulation 10: 222
- lipid lowering drugs 10: 220-222
- clofibrate 10: 220-224, 235-236
- nicotinic acid 10: 220-224, 235-236

Heart failure, refractory

- nitroprusside 9: 385-386

Heart valve lesions

- in methysergide therapy 9: 156-157

Heparin

- platelet function 9: 51-52
- thromboses 9: 60

Hepatic dysfunction

- see liver disease

Hepatic encephalopathy

- neomycin 10: 107

Hepatitis, acute viral

- petidine elimination 10: 457-458

Herpes zoster

- idoxuridine 9: 395

Hetacillin 9: 83; 10: 27

Hydrochlorothiazide-triamterene combination

- compared with
- spironolactone 9: 232-233
- hypertension, essential 9: 232-233

Hydroxychloroquine

- thrombosis, venous 9: 57

Hyperlipidaemia

- dietary fat 9: 233-234

Hypertension

- β -blockers 9: 153

contraceptives, oral 9: 230-231

- diuretics 9: 203-206
- timolol 9: 165-168

Hypertension, essential

- treatment 9: 232-233

Hyperuricaemia

- aetiology 9: 145-151
- alcohol 9: 148-149
- diet 9: 148
- endocrine disorders 9: 149
- over-production of urate 9: 149
- hypertension 9: 148
- obesity 9: 148
- type IV hyperlipoproteinaemia 9: 148
- under-excretion of urate 9: 149-150
- complications if untreated 9: 142-143
- complications of gout 9: 142-143
- degenerative vascular disease 9: 143
- gouty arthritis 9: 142
- treatment 9: 141-152
- reasons for hesitation 9: 144

Hyperuricaemia, asymptomatic

- treatment 9: 144-145, 150

Hypnotic drugs 9: 464-474

Hypokalaemia

- diuretics 9: 161-162
- furosemide therapy 9: 231-232

Hypovolaemia

- analgesia, postoperative 9: 375

I

Ibuprofen

- rheumatic disorders 9: 321-322; 10: 410
- compared with
- naproxen 9: 349-351

Idoxuridine

- herpes zoster 9: 395

IgE-associated hypersensitivity

- secretory otitis media 9: 314-315

Imidazole derivatives

- fungal infections 9: 402-405
- clotrimazole 9: 403
- econazole 9: 404
- levamisole 9: 402
- mebendazole 9: 402-403
- miconazole 9: 403
- tetramisole 9: 402
- thiabendazole 9: 402
- tinidazole 9: 403

Imipramine

- children, hyperactive 9: 236-237

Imipramine poisoning

- cardiac massage 10: 228-229

Immune reactions

- practolol 10: 336-340

Immunisation, rubella 9: 390-391

Immunosuppressive agents

- + anticoagulants
- glomerulonephritis, rapidly progressive 10: 156-157

rheumatoid arthritis 10: 418-420

Immunotherapy

BCG

leukaemia, myeloblastic 9: 391-392

Indomethacin

compared with

ketoprofen 10: 153

platelet function 9: 38-43

rheumatic disorders 10: 408-409

compared with

naproxen 9: 349

thromboses, renal 9: 56

Indomethacin, topical

sunburn 9: 158

Inflammatory dermatoses

bufexamac 10: 353-355

Insomnia 9: 459-462

Intramuscular injection

absorption 10: 67-68

Iron

resistance to infection 10: 75-76

Ischaemia, transient cerebral

sulphinpyrazone 9: 57

Islet cell transplantation

diabetes, experimental 10: 151

J

Jaundice, postoperative

anaesthesia, halothane 9: 311-313

K

Kanamycin 10: 94-98

Ketoprofen

compared with

indomethacin 10: 153

rheumatic disorders 9: 322; 10: 412

L

Labour, premature

inhibiting agents 9: 389-390

Lactation 10: 121-129

maintenance 10: 122-123

milk ejection reflex 10: 122

pregnancy 10: 121-122

Lactation, inhibition of

methods 10: 124-129

brom-ergocryptine 10: 128-129

chlorotrianesene 10: 126-127

no-sucking technique 10: 124

oestrogens 10: 124-126

thromboembolism, puerperal 10: 125-126

oestrogen combinations 10: 127-128

quinestrol 10: 127

Leukaemia, acute

children

corticosteroids 10: 433

Leukaemia, myeloblastic

remission

BCG therapy 9: 391-392

Lidoflazine

platelet function 9: 47

Lincomycin 10: 42-45

drug reactions, adverse

colitis 10: 331-332

respiratory infections 10: 444

Lipid lowering drugs

clofibrate

heart disease 10: 220-224, 235-236

nicotinic acid

heart disease 10: 220-224, 235-236

Lipid metabolism

fenfluramine 10: 255-256

Liver disease

drug metabolism, impairment of 10: 68

jaundice, postoperative

anaesthesia, halothane 9: 311-313

minocycline

absorption 9: 265-267

oestrogen metabolism 9: 227

pethidine elimination 10: 457-458

vomiting in late pregnancy 9: 303

Liver disease, cholestatic

phenobarbitone effects 10: 453-454

Liver disease, postoperative

halothane 10: 233-235

M

Macrolides 10: 39-42

Malaria

minocycline 9: 282-283

Mebendazole

fungal infections 9: 402-403

Meclofenamic acid

rheumatoid arthritis 10: 413

Mefenamic acid

pharmacology 10: 376

rheumatoid arthritis 10: 413

Meningococcal carriers

minocycline 9: 282

Meningococcal infections

penicillins, natural 10: 15

Mephenesin

spasticity 10: 117-118

Metabolic activation

drug toxicity 10: 454-456

Metampicillin 9: 83

Methaqualone

+ diphenhydramine

sleep 9: 470

Methicillin 10: 19-20

Methoxsalen

psoriasis 10: 73-74

Methylphenidate

children, hyperactive 9: 237

Methypyrone

sleep 9: 470

Methysergide

causing heart valve lesions 9: 156-157

compared with

clonidine, low-dose 10: 361

Miconazole 9: 403, 407-422

administration 9: 421-422

nail infections 9: 421-422

- skin infections 9: 421
 - vaginal infections 9: 421
 - antimicrobial activity 9: 407-411
 - antibacterial activity 9: 410
 - antifungal activity 9: 407-409
 - in vitro* 9: 407-409
 - in vivo* 9: 409
 - mode of action 9: 410
 - resistance 9: 411
 - drug reactions, adverse 9: 420-421
 - pharmacokinetic studies 9: 411
 - administration, oral 9: 411
 - application, topical 9: 411
 - therapeutic trials 9: 412-420
 - nail infections 9: 417-419
 - skin infections 9: 415-417
 - systemic fungal infections 9: 419-420
 - vaginal infections 9: 413-415
 - candidiasis 9: 413-415
 - compared with
 - other agents 9: 415
 - other 9: 415
 - toxicology studies 9: 411-412
 - dysmorphology and reproduction 9: 412
 - toxicity, acute 9: 411-412
 - toxicity, chronic 9: 412
 - Migraine
 - monoamine oxidase 9: 315-316
 - prophylaxis
 - clonidine, low-dose 10: 358-365
 - Minocycline 9: 256-288
 - absorption 9: 263-267
 - half-life in renal or hepatic failure 9: 266-267
 - renal or hepatic failure 9: 265
 - serum half-life 9: 265-266
 - antibacterial action 9: 261-262
 - antimicrobial activity, *in vitro* 9: 256-263
 - antibacterial activity, *in vitro* 9: 263
 - anaerobic bacteria 9: 261
 - Candida* 9: 260-261
 - effect of inoculum size, media and pH 9: 262
 - Gram-negative bacteria 9: 259-260
 - Gram-positive bacteria 9: 256-259
 - Staphylococcus aureus* 9: 256-258
 - streptococci 9: 258-259
 - resistance 9: 262-263
 - distribution 9: 267-270
 - amniotic fluid 9: 269
 - bile, liver and gallbladder 9: 267
 - breast milk 9: 269
 - cerebrospinal fluid 9: 267
 - cord serum 9: 269
 - other tissues and fluids 9: 269
 - protein binding 9: 269-270
 - reproductive organs 9: 268-269
 - sputum and upper respiratory tract 9: 268
 - dosage 9: 287-288
 - intravenous 9: 288
 - oral 9: 287
 - drug interactions 9: 286-287
 - drug reactions, adverse 9: 284-286
 - gastro-intestinal disturbances 9: 284-285
 - miscellaneous 9: 286
 - skin 9: 286
 - vestibular effects 9: 285-286
 - excretion 9: 270-273
 - effect of dialysis 9: 272-273
 - faeces 9: 271-272
 - urine 9: 270-271
 - metabolism 9: 270
 - pharmacokinetics 9: 263-273
 - precautions 9: 287
 - renal failure 9: 273
 - therapeutic trials 9: 273-284
 - cholera 9: 283
 - gonorrhoea 9: 276-277
 - intravenous minocycline 9: 284
 - malaria 9: 282-283
 - meningococcal carriers 9: 282
 - miscellaneous infections 9: 283-284
 - non-specific urethritis 9: 278
 - respiratory tract infections 9: 278-281
 - caused by tetracycline-resistant bacteria 9: 281
 - lower respiratory tract 9: 278-280
 - upper respiratory tract 9: 280-281
 - skin and soft tissue infections 9: 281-282
 - urinary tract infections 9: 273-276
 - Monoamine oxidase
 - migraine 9: 315-316
 - Morphine
 - combined with
 - doxapram 9: 228-230
 - naloxone 9: 228-230
 - pain relief, postoperative 9: 228-230
 - Muscle relaxants
 - rheumatoid arthritis 10: 415
 - Myocardial infarction
 - see heart disease
- N
- Nail infections
 - candidal paronychia
 - clotrimazole 9: 441
 - miconazole 9: 417-419
 - Nalidixic acid 10: 49-50
 - Naproxen 9: 330-360
 - dosage 9: 360
 - drug interactions 9: 359-360
 - drug reactions, adverse 9: 357-359
 - central nervous system 9: 358
 - gastro-intestinal 9: 358
 - pharmacodynamics, human 9: 335-337
 - bleeding time and platelet aggregation, effect on 9: 336-337
 - collagen metabolism, effect on 9: 335
 - gastric mucosa and blood loss, effect on 9: 335-336
 - pharmacodynamic studies, animal 9: 330-334
 - analgesic activity 9: 331
 - anti-inflammatory activity 9: 330-331
 - antipyretic effect 9: 331-332
 - gastric mucosa, effect on 9: 332-333
 - immunological effects 9: 332

- mode of action 9: 333–334
 - pharmacokinetics, animal 9: 334–335
 - absorption 9: 334
 - distribution 9: 334–335
 - excretion 9: 335
 - metabolism 9: 335
 - pharmacokinetics, human 9: 338–341
 - absorption 9: 338–340
 - antacids 9: 339–340
 - bioavailability 9: 339
 - effect of food 9: 338
 - plasma half-life 9: 340
 - breast milk 9: 341
 - excretion 9: 341
 - metabolism 9: 341
 - placental transfer 9: 341
 - plasma protein binding 9: 341
 - precautions 9: 360
 - rheumatic disorders 9: 322, 342–355; 10: 410–411
 - therapeutic trials 9: 342–356
 - ankylosing spondylitis 9: 351–352
 - gout, acute 9: 354–355
 - osteoarthritis 9: 352–354
 - pain states 9: 355–356
 - rheumatoid arthritis 9: 342–351
 - + aspirin 9: 348–349
 - compared with
 - aspirin 9: 347–348
 - fenoprofen 9: 349–351
 - flufenamic acid 9: 351
 - ibuprofen 9: 349–351
 - indomethacin 9: 349
 - open studies, long-term 9: 343–345
 - open studies, short-term 9: 342–343
 - placebo-controlled trials 9: 345–347
- Nausea**
- in pregnancy 9: 299–305
- Neomycin** 10: 106–108
- Neonate**
- amoxycillin 9: 111
- Nephropathy, analgesic**
- aspirin 10: 69–70
- Nephrotic syndrome**
- children
 - corticosteroids 10: 435–436
- Neurotransmission**
- dopamine 10: 458–459
- Nicotine**
- platelet aggregation 9: 34
- Nicotinic acid**
- heart disease 10: 220–224, 235–236
- Nitrazepam** 9: 467–468
- Nitrofurantoin**
- platelet function 9: 48
- Nitroprusside**
- in refractory heart failure 9: 385–386
- Nitrous oxide**
- in morphine anaesthesia
 - cardiovascular effects 9: 383–385
- Non-compliance**
- antidepressants 10: 68
- Non-specific urethritis**
- minocycline 9: 278

O

- Obesity, adult**
- fenfluramine 10: 249–250, 270–292
 - cardiovascular disorders 10: 289–290
 - corticosteroid therapy 10: 290–291
 - hypertension 10: 287–289
 - motor disorders 10: 291–292
 - pregnancy 10: 292
 - psychiatric disorders 10: 292
 - pulmonary disease 10: 290
- Obesity, childhood**
- fenfluramine 10: 292–295
- Oedema**
- diuretics 9: 195–202
- Oestrogens**
- hepatic metabolism 9: 227
 - lactation, inhibition of 10: 124–126
 - platelet aggregation 9: 33
- Oestrogen combinations**
- lactation, inhibition of 10: 127–128
- Oral ulceration, recurrent**
- diagnosis 9: 396–397
 - treatment 9: 396–397
- Osteoarthritis**
- antirheumatic drugs 10: 421–422
 - naproxen 9: 352–354
- Otitis, external**
- treatment 9: 393–395
- Otitis media**
- management 10: 449–450
- Otitis media, secretory**
- IgE-associated hypersensitivity 9: 314–315
- Oxolinic acid** 10: 50
- Oxyphenbutazone**
- rheumatoid arthritis 10: 408
- Oxytetracycline**
- purpura, thrombocytopenic 10: 232

P

- Paediatrics**
- corticosteroids, use of 10: 426–436
 - rheumatoid arthritis 10: 420
 - secretory otitis media 9: 314–315
 - typhoid fever 9: 317
- Pain relief**
- analgesics, mild 10: 373–381, 388–390
- Pain relief, postoperative**
- morphine combined with doxapram 9: 228–230
 - morphine combined with naloxone 9: 228–230
- Paracetamol**
- pharmacology 10: 376
 - rheumatoid arthritis 10: 414
- Paracetamol overdosage**
- drug metabolism 10: 229–230
- Paromomycin** 10: 106–108
- Paronychia, chronic** 10: 140–141
- D-Penicillamine**
- rheumatic disorders 9: 324; 10: 419–420

- Penicillin G
 platelet function 9: 50
 Penicillins
 amoxycillin 9: 93-135
 ampicillin 9: 93-111, 117-133
 distribution
 protein binding 9: 308-309
 volume of distribution 9: 308-309
 drug reactions, adverse
 colitis 10: 330-332
 pharmacology 9: 81-87
 respiratory infections 10: 441
 + streptomycin
 respiratory infections 10: 444
 therapeutic use 9: 81-87
 Penicillins, natural
 benzylpenicillin 10: 9-18
 phenoxymethylpenicillin 10: 9-18
 Penicillins, semi-synthetic 10: 18-28
 Peptide antibiotics 10: 89-91
 Peptides, vasoactive
 platelet aggregation 9: 31
 Pethidine
 viral hepatitis, acute 10: 457-458
 Phenacetin
 pharmacology 10: 376
 Phenformin + ethyloestrenol
 platelet function 9: 50
 Phenobarbitone
 liver disease, cholestatic 10: 453-454
 Phenothiazines
 sleep 9: 471-472
 Phenylbutazone
 acetanilide oxidation 9: 310-311
 anaemia, hypoplastic 9: 310-311
 platelet function 9: 38-43
 rheumatoid arthritis 10: 408
 Phenylalkanoic acids
 fenoprofen
 rheumatoid arthritis 10: 410
 flurbiprofen
 rheumatoid arthritis 10: 412
 ibuprofen
 rheumatoid arthritis 10: 410
 ketoprofen
 rheumatoid arthritis 10: 412
 naproxen
 rheumatoid arthritis 10: 410-411
 Phorbol myristate
 platelet aggregation 9: 33
 Photochemotherapy
 psoriasis 10: 73-74
 Physostigmine
 tricyclic antidepressant poisoning 10: 226-227
 Pindolol
 compared with
 clonidine, low-dose 10: 360-361
 timolol 9: 165-166
 Pivampicillin 9: 83-84; 10: 27
 Pizotifen
 compared with
 clonidine, low-dose 10: 362
 Plague
 streptomycin 10: 93
 Platelets
 aggregation 9: 28-34
 ADP 9: 28-30
 adrenaline 9: 31
 nicotine smoking 9: 34
 oestrogens 9: 33
 phorbol myristate 9: 33
 ristocetin 9: 32
 serotonin 9: 31
 vasoactive peptides 9: 32
 blood coagulation 9: 34-36
 release reaction 9: 27-28
 thrombosis 9: 19-76
 role in 9: 21-26
 Platelet function
 drugs which inhibit 9: 36-51
 adrenergic receptor blocking drugs 9: 52
 alcohol 9: 48
 anaesthetics, general 9: 48
 anti-inflammatory drugs, non-steroid 9: 38-43
 antiserotonin agents 9: 53
 aspirin 9: 38-43
 chloroquine 9: 44
 chlorpromazine 9: 48
 clofibrate 9: 49
 dextran 9: 49
 dipyridamole 9: 44-46
 diuretics 9: 48
 fibrinogen degradation products 9: 50
 glucagon 9: 53
 guaiaphenesin 9: 49
 heparin 9: 51-52
 indomethacin 9: 38-43
 lidoflazine 9: 47
 nitrofurantoin 9: 48
 penicillin G 9: 50
 phenformin + ethyloestrenol 9: 50
 phenylbutazone 9: 38-43
 prostaglandins 9: 46-47
 pyridinolcarbamate 9: 49
 pyrimido-pyrimidines 9: 44-46
 sulphinpyrazone 9: 38-43
 tricyclic antidepressants 9: 47
 Pneumonia
 management 10: 445-447
 Poisoning, management of
 haemoperfusion, charcoal 10: 143-144
 Poisoning, paraquat
 treatment 9: 307
 Polymixins
 see peptide antibiotics
 Polymyalgia rheumatica
 antirheumatic drugs 10: 422
 Potassium supplementation
 frusemide therapy, long-term 9: 231-232
 Practolol 10: 336-341
 drug reactions, adverse 10: 336-341
 ocular reactions 10: 149-151
 skin reactions 10: 149-151
 Prazosin
 compared with other antihypertensives 9: 158

- Prednisolone
 typhoid fever
 hyperpyrexia 9: 317
- Pregnancy
 amoxycillin 9: 108-109
 anaesthetics 10: 152
 congenital malformations 10: 148-149
 diuretics 9: 207-208
 fenfluramine 10: 292
 incidence of vomiting 9: 300-301
 labour, premature
 inhibiting agents 9: 389-390
 lactation 10: 121-122
 minocycline
 distribution 9: 269
 naproxen
 pharmacokinetics 9: 341
 rubella immunisation 9: 390-391
 vomiting 9: 299-306
 aetiology 9: 301-303
 in late pregnancy 9: 303
 non-pregnancy causes 9: 302
 physiological changes 9: 301-302
 psychological factors 9: 302
 vomiting centres 9: 301
 hyperemesis gravidarum 9: 300
 in early pregnancy 9: 299
 management 9: 303-306
 in early pregnancy 9: 303-305
 severe vomiting 9: 306
- Prophylaxis, antibiotic
 in surgical patients 10: 154-155, 333-335
- Prophylaxis, migraine
 clonidine, low-dose 10: 358-365
- Propranolol
 compared with
 timolol 9: 165-173
- Prostaglandins
 joint inflammation 10: 402-403
 platelet function 9: 39-40, 46-47
- Psoriasis
 buxefamac 10: 354
 photochemotherapy 10: 73-74
- Psychiatric disorders
 fenfluramine
 alcoholism 10: 302
 amphetamine-dependence 10: 300-301
 anxiety 10: 300
 mania 10: 300
 tobacco-dependence 10: 301
- Purpura, idiopathic thrombocytopenic
 children
 corticosteroids 10: 433-434
- Purpura, thrombocytopenic
 oxytetracycline-induced 10: 232
- Pyelonephritis
 kanamycin 10: 97
- Pyoderma
 antibiotics, topical 9: 157
- Pyridinolcarbamate
 platelet function 9: 49
- Pyrimido-pyrimidines
 platelet function 9: 44-46
- Q
- Quinestrol
 lactation, inhibition of 10: 127
- Quinidine elimination
 in congestive heart failure 9: 154
 in renal failure 9: 154
- R
- Renal failure
 amoxycillin
 absorption 9: 104-105
 excretion 9: 110-111
 aspirin 10: 69-70
 β -blockers 9: 153
 diuretics 9: 162-163, 206-207
 minocycline 9: 273
 absorption 9: 265-267
 quinidine elimination 9: 154
- Renal failure, acute
 haemolysis, glycerol-induced 9: 313-314
- Respiratory disease
 analgesia, postoperative 9: 375
- Respiratory infections 10: 437-450
 antibiotic sensitivity tests 10: 445
 management 10: 445-450
 bronchial infections 10: 448-449
 acute exacerbation of chronic infections 10: 449
 acute infections 10: 448-449
 chronic infections 10: 449
 bronchopneumonia 10: 447-448
 treatment 10: 448
 failure to respond to treatment 10: 450
 otitis media 10: 449-450
 pneumonia 10: 445-447
 diagnosis 10: 446
 treatment 10: 446-447
 sinusitis 10: 449
- organisms, pathogenic 10: 437-441
 Friedlander's bacillus 10: 440
 fungi 10: 441
 haemophilus influenzae 10: 439
 infections 10: 439
 sensitivity to antibiotics 10: 439
 mycoplasma pneumoniae 10: 441
 pneumococci 10: 438
 infections 10: 438
 sensitivity to antibiotics 10: 438
 pseudomonas aeruginosa 10: 440
 staphylococcus aureus 10: 439
- sputum cultures 10: 445
- therapeutics 10: 441-450
 ampicillin 10: 442
 cephalosporins 10: 444
 chloramphenicol 10: 443
 clindamycin 10: 444
 co-trimoxazole 10: 443
 erythromycin 10: 443
 lincomycin 10: 444

- minocycline 9: 278-281
 penicillin 10: 441
 penicillin + streptomycin 10: 444
 tetracyclines 10: 442-443
 Rheumatic disorders 9: 321-325
 naproxen 9: 342-355
 Rheumatoid arthritis
 antirheumatic drugs 10: 405-420
 pharmacokinetics 10: 403-404
 treatment at level 1 10: 406-408
 general basic treatment 10: 406
 salicylates 10: 69-70, 406-408
 treatment at level 2 10: 408-415
 anthranilic acids 10: 413
 mefenamic acid 10: 413
 mefenamic acid 10: 413
 flufenamic acid 10: 413
 antimalarials 10: 413-414
 corticosteroids, intra-articular 10: 414
 indomethacin 10: 153, 408-409
 muscle relaxants 10: 415
 non-narcotic analgesics 10: 414
 dextropropoxyphene 10: 414
 paracetamol 10: 414
 others with mild anti-inflammatory activity 10: 412
 alclofenac 10: 412
 tolmetin 10: 412
 oxyphenbutazone 10: 408
 phenylalkanoic acids 10: 409-412
 fenoprofen 10: 410
 flurbiprofen 10: 412
 ibuprofen 10: 410
 ketoprofen 10: 153, 412
 naproxen 9: 342-351; 10: 410-411
 phenylbutazone 10: 408
 tranquillisers 10: 415
 treatment at level 3 10: 415-417
 adrenocorticotrophic hormone 10: 417
 corticosteroids, oral 10: 416-417
 gold salts 9: 155-156; 10: 415-416
 treatment at level 4
 hospitalisation 10: 418
 treatment at level 5 10: 418-420
 azathioprine 10: 419
 cyclophosphamide 10: 418-419
 D-penicillamine 10: 419-420
 children
 corticosteroids 10: 436
 pathogenesis 10: 397-400
 allergic arthritis 10: 400
 biochemical or endocrine factors 10: 399
 hereditary factors 10: 399
 infectious agents 10: 398-399
 immunological factors 10: 397-398
 neurogenic factors 10: 400
 proliferative disorders 10: 399-400
 trauma 10: 399
 pharmacology of joint inflammation 10: 400-403
 kalikrein-kinin-kininase system 10: 400-401
 lysosomes 10: 401-402
 prostaglandins 10: 402-403
 protein binding 10: 402
 Rheumatic carditis
 children
 corticosteroids 10: 432-433
 Rhinitis, allergic
 beclomethasone dipropionate intranasal 10: 212-216
 Rhinitis, perennial
 beclomethasone dipropionate intranasal 10: 214-216
 Ristocetin
 platelet aggregation 9: 32
 Rubella immunisation 9: 390-391
- S
- Salicylates
 rheumatic disorders 9: 323-324; 10: 406-408
 Secretory otitis media
 IgE-associated hypersensitivity 9: 314-315
 Sex hormones, synthetic
 drug reactions, adverse 10: 153-154
 Sinusitis
 management 10: 449
 Skin infections
 antibiotics, peptide 10: 90
 children
 corticosteroids 10: 431
 clotrimazole 9: 438-441
 fenfluramine
 acne vulgaris 10: 302
 pigmented naevi 10: 303
 psoriasis 10: 302-303
 miconazole 9: 415-417
 minocycline 9: 281-282
 Sleep
 enuresis 9: 463
 management 9: 475
 habits 9: 455-456
 adults 9: 456
 children 9: 456
 hypersomnia 9: 463
 management 9: 474-475
 hypnotic drugs 9: 464-474
 amphetamine derivatives 9: 472
 antidepressants 9: 471
 monoamine oxidase inhibitors 9: 471
 tricyclic 9: 471
 barbiturates 9: 465-467
 drug reactions, adverse 9: 467
 sleep patterns, effect on 9: 465
 toxicity 9: 467
 benzodiazepines 9: 467-468
 drug reactions, adverse 9: 468
 toxicity 9: 468
 sleep patterns, effect on 9: 468
 chloral hydrate 9: 469
 drug reactions, adverse 9: 469
 sleep patterns, effect on 9: 469
 ethyl alcohol 9: 472
 hot milk drinks 9: 472
 other non-barbiturate hypnotics 9: 469-471
 anticholinergics 9: 470-471
 antihistamines 9: 470-471
 carbromal 9: 470

- ethchlorvynol 9: 471
 - glutethimide 9: 470
 - methaqualone
 - + diphenhydramine 9: 470
 - methypyrilone 9: 470
 - phenothiazines 9: 471-472
 - insomnia 9: 459-462
 - extrinsic factors 9: 459-460
 - altitude 9: 460
 - climate 9: 460
 - noise 9: 459-460
 - intrinsic factors 9: 460-462
 - age 9: 460
 - central nervous system 9: 462
 - heart disease 9: 462
 - psychiatric illnesses 9: 461-462
 - psychological disorders 9: 460-461
 - management 9: 473-474
 - 'electrosleep' therapy 9: 473-474
 - hypnotic drugs, use of 9: 474
 - re-establishment of normal habits 9: 473
 - narcolepsy 9: 463-464
 - management 9: 475
 - needs 9: 456-458
 - deprivation, effect of 9: 457-458
 - deprivation of REM sleep 9: 458
 - nightmares 9: 463
 - night terrors 9: 463
 - management 9: 474
 - physiology 9: 451-455
 - body function, changes in 9: 451-452
 - brain activity 9: 451-452
 - stages of sleep 9: 452
 - stages of the brain and body 9: 452-455
 - NREM sleep 9: 454
 - REM sleep 9: 454-455
 - wakefulness 9: 453-454
 - snoring 9: 463
 - somnambulism 9: 463
 - management 9: 474
 - Sodium valproate
 - epilepsy 9: 387-389
 - Soft tissue infections
 - minocycline 9: 281-282
 - Spasticity 10: 112-120
 - pathophysiology 10: 112-114
 - cerebral spasticity 10: 114
 - spinal spasticity 10: 114
 - stretch reflex arc 10: 113
 - pharmacological agents 10: 117-120
 - α -adrenergic blocking drugs 10: 120
 - baclofen 10: 118
 - dosage 10: 118
 - drug reactions, adverse 10: 118
 - dantrolene sodium 10: 119
 - dosage 10: 119
 - drug reactions, adverse 10: 119
 - diazepam 10: 117-118
 - dosage 10: 117-118
 - mephenesin 10: 117
 - phenothiazines 10: 119-120
 - sclerosant agents 10: 116-117
 - injection, intrathecal 10: 116
 - injection of motor points or nerves 10: 117
 - surgery 10: 116
 - therapeutics 10: 115-116
 - Spiramycin 10: 42
 - Spirolactone 9: 193
 - compared with
 - hydrochlorothiazide-triamterene combination 9: 232-233
 - drug reactions, adverse 9: 214-215
 - hypertension, essential 9: 232-233
 - Serotonin
 - platelet aggregation 9: 31
 - Streptococcal infections
 - penicillins, natural 10: 15
 - Streptomycin 10: 92-94
 - + penicillin
 - respiratory infections 10: 444
 - Sulphinpyrazone
 - platelet function 9: 39-43
 - thrombo-embolic disorders 9: 56
 - Sunburn
 - indomethacin, topical 9: 158
 - Surgery
 - analgesia, postoperative 9: 373-380
 - antibiotics, prophylactic 10: 154-155, 333-335
 - Systemic lupus erythematosus
 - pathogenesis 10: 397-400
- T
- Tetracyclines 10: 35-39
 - drug reactions, adverse
 - colitis 10: 330-331
 - minocycline 9: 256-288
 - respiratory infections 10: 443
 - Theophylline
 - metabolism 9: 381-382
 - toxicity 9: 381-382
 - Thiabendazole
 - fungal infections 9: 402
 - Thrombocytopenia, purpuric
 - oxytetracycline-induced 10: 232
 - Thrombo-embolic disease
 - anticoagulants + antiplatelet drugs 9: 60-61
 - antiplatelet drugs 9: 54-61
 - clofibrate 9: 59
 - dextran 9: 59
 - dipyridamole 9: 58
 - dipyridamole + aspirin 9: 60
 - Thromboembolism, puerperal
 - oestrogens 10: 126
 - Thromboses, arterial
 - aspirin 9: 55-56
 - Thromboses, renal
 - indomethacin 9: 56
 - Thromboses, venous
 - aspirin prophylaxis 9: 55
 - heparin 9: 60
 - hydroxychloroquine 9: 57
 - Thrombosis
 - platelets, role in 9: 21-26
 - prophylactic drugs 9: 1-3, 54-61

- Thrombosis, coronary
 see heart disease
- Thyroid status, influence on
 antipyrine half-life 9: 228
- Timolol 9: 165-176
 animal pharmacology 9: 173-174
 antiarrhythmic effect 9: 173
 antihypertensive effect of hydralazine 9:
 174
 β -blocking effect 9: 172
 bronchial β -receptors 9: 174
 cardiac depressant effect 9: 173
 heart rate and cardiac output 9: 173
 plasma renin activity 9: 174
 stroke volume and peripheral vascular resistance
 9: 173
 compared with
 alprenolol 9: 165-166
 pindolol 9: 165-166
 propranolol 9: 165-173
 contra-indications 9: 175
 dosage 9: 176
 angina 9: 176
 hypertension 9: 176
 drug interactions 9: 176
 drug reactions, adverse 9: 175
 pharmacokinetics 9: 174-175
 animal studies 9: 174
 human studies 9: 174-175
 pharmacology, human 9: 169-172
 β -adrenergic blocking activity 9: 169-170
 blood pressure 9: 171
 bronchial smooth muscle 9: 172
 heart rate and cardiac output 9: 170-171
 membrane stabilising and partial agonist activity
 9: 172
 plasma renin activity 9: 172
 sympathetic reflex tachycardia 9: 171
 precautions 9: 175-176
 therapeutic trials 9: 165-169
 angina pectoris 9: 168-169
 hypertension 9: 165-168
 combined with thiazide diuretics 9: 168
- Tinea
 clotrimazole 9: 439-440
 miconazole 9: 416-417
- Tinea barbae 10: 137
- Tinea capitis 10: 131-134
- Tinea corporis 10: 134
- Tinea cruris 10: 134-135
- Tinea faciei 10: 137-138
- Tinea imbricata 10: 138-139
- Tinea pedis 10: 135-136
- Tinea unguium 10: 137
- Tinea versicolor 10: 138
- Tobramycin 10: 103-106
- Tolmetin
 rheumatoid arthritis 10: 412
- Total body potassium
 frusemide therapy, long-term 9: 231-232
- Toxicity
 metabolic activation 10: 454-456
 theophylline 9: 381-382
- Tranquillisers
 aggression 10: 157
 rheumatoid arthritis 10: 415
- Triacetyloleandomycin 10: 42
- Triamterene 9: 193-194
 drug reactions, adverse 9: 215
- Tuberculosis 9: 364-371
 drug treatment 9: 364-371
 adverse reactions 9: 369-370
 assessment of progress 9: 370-371
 availability of drugs 9: 364
 chemotherapy, intermittent 9: 369
 drug regimens, standard 9: 365-367
 continuation phase 9: 367
 intensive phase 9: 367
 duration of chemotherapy 9: 371
 other regimens 9: 367-368
 personnel 9: 365
 reserve regimens 9: 368
- Tuberculosis
 streptomycin 10: 93
- Tularaemia
 streptomycin 10: 93
- Typhoid fever 9: 241-249, 316-317
 aetiology 9: 241, 243, 247, 317
 carriers, human 9: 241-249, 317
 treatment 9: 242-246, 248-249, 317
 Egypt 9: 247-249
 paediatrics 9: 317
 treatment 9: 241-246, 248-249, 317
 ampicillin 9: 241-242, 244-245, 248-249, 317
 chloramphenicol 9: 241-242, 244-246, 248, 317
 co-trimoxazole 9: 241-242, 244-246, 248-249,
 317
 prednisolone 9: 317
 Southeast Asia 9: 241-246
 Philippines 9: 245-246
 South Vietnam 9: 241-242
 Thailand 9: 243-245
- U
- Ulcer, peptic 10: 56-65
 management 10: 56-61
 antacids 10: 58-60
 antacid preparations 10: 58
 complications 10: 58-59
 current status 10: 59-60
 ulcer healing 10: 58
 anticholinergic drugs 10: 60-61
 anticholinergic preparations 10: 60
 complications 10: 60
 contra-indications 10: 61
 carbenoxolone sodium 10: 57
 complications 10: 57
 current status 10: 57-58
 duodenal ulcer 10: 57
 gastric ulcer 10: 57
 hospital admission 10: 56-57
 smoking, cessation of 10: 61
 new drugs 10: 64-65
 amylopectin sulphate 10: 64

- deglycyrrhizinated liquorice 10: 64-65
 - gefarnate 10: 64
 - histamine receptor antagonists 10: 65
 - metoclopramide 10: 65
 - prostaglandins 10: 65
 - secretin 10: 65
 - tripotassium dicitrate bismuthate 10: 65
 - zinc sulphate 10: 64
 - treatment 10: 61-64
 - blood transfusion 10: 61
 - perforation 10: 63
 - stenosis 10: 63-64
 - surgery 10: 62-63
 - upper gastro-intestinal haemorrhage 10: 61
 - Ulcerative colitis
 - children
 - corticosteroids 10: 433
 - Ultraviolet radiation, long-wave
 - psoriasis 10: 73-74
 - Urinary tract infections
 - antibiotics, peptide 10: 90
 - antimicrobial prophylaxis 9: 386-387
 - contraceptives, oral 10: 72-73
 - co-trimoxazole 10: 31
 - co-trimoxazole + azathioprine 10: 71-72
 - gentamicin 10: 102
 - minocycline 9: 273-276
 - Urticaria 9: 292-298
 - angio oedema 9: 292-293
 - diagnosis 9: 293-297
 - desensitisation plan 9: 296
 - drug withdrawal plan 9: 294-295
 - food plan 9: 295-296
 - infection plan 9: 296
 - miscellaneous plan 9: 296
 - 'nerves' plan 9: 297
 - drug treatment 9: 297-298
 - anxiety agents and antidepressants 9: 297
 - antihistamines 9: 297
 - ephedrine 9: 297
 - hydroxyzine 9: 297
 - treatment, external 9: 297-298
 - Urticaria, cholinergic and physical 9: 298
- V
- Vaginal infections
 - clotrimazole 9: 434-438
 - miconazole 9: 413-415
 - Varicose veins
 - compression sclerotherapy 9: 392-393
 - Vertigo
 - minocycline 9: 285-286
 - Viral hepatitis, acute
 - pethidine elimination 10: 457-458
 - Vomiting
 - in pregnancy 9: 299-306
- W
- Wood's light
 - fungal skin infections 10: 131, 133, 138, 141-142

